Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney | 23 | 2023 | 153 | 3.750 |
Why?
|
Kidney Diseases | 15 | 2014 | 72 | 2.580 |
Why?
|
Glomerulosclerosis, Focal Segmental | 21 | 2012 | 32 | 2.310 |
Why?
|
Lupus Nephritis | 16 | 2019 | 27 | 2.140 |
Why?
|
Peritoneal Dialysis | 17 | 2011 | 26 | 1.780 |
Why?
|
Biopsy, Needle | 9 | 2021 | 105 | 1.770 |
Why?
|
Kidney Failure, Chronic | 22 | 2012 | 124 | 1.290 |
Why?
|
Biopsy | 14 | 2018 | 201 | 1.180 |
Why?
|
Nephrology | 4 | 2018 | 11 | 1.140 |
Why?
|
Proteinuria | 12 | 2019 | 50 | 1.130 |
Why?
|
Prognosis | 25 | 2023 | 785 | 1.120 |
Why?
|
Glomerulonephritis | 12 | 2007 | 14 | 1.110 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 12 | 2002 | 13 | 1.100 |
Why?
|
Kidney Glomerulus | 19 | 2023 | 40 | 1.080 |
Why?
|
Humans | 111 | 2023 | 27072 | 0.970 |
Why?
|
Glomerulonephritis, IGA | 3 | 2023 | 7 | 0.950 |
Why?
|
Adult | 69 | 2021 | 7831 | 0.940 |
Why?
|
Creatinine | 13 | 2019 | 42 | 0.800 |
Why?
|
Peritonitis | 7 | 2002 | 17 | 0.780 |
Why?
|
Renal Dialysis | 9 | 2012 | 84 | 0.770 |
Why?
|
Nephrosis, Lipoid | 5 | 2019 | 11 | 0.770 |
Why?
|
Needles | 2 | 2021 | 20 | 0.760 |
Why?
|
Male | 64 | 2021 | 14772 | 0.760 |
Why?
|
Middle Aged | 50 | 2021 | 8923 | 0.750 |
Why?
|
Hematuria | 6 | 2014 | 15 | 0.730 |
Why?
|
Acute Kidney Injury | 4 | 2019 | 38 | 0.710 |
Why?
|
Steroids | 6 | 2012 | 23 | 0.700 |
Why?
|
Female | 66 | 2021 | 15212 | 0.680 |
Why?
|
Nephrotic Syndrome | 8 | 2019 | 23 | 0.650 |
Why?
|
Immunosuppressive Agents | 8 | 2023 | 120 | 0.620 |
Why?
|
Nephrologists | 1 | 2018 | 3 | 0.620 |
Why?
|
Radiologists | 1 | 2018 | 8 | 0.620 |
Why?
|
Scleroderma, Limited | 1 | 2018 | 3 | 0.620 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2019 | 44 | 0.610 |
Why?
|
Practice Patterns, Physicians' | 1 | 2018 | 111 | 0.560 |
Why?
|
Prospective Studies | 10 | 2021 | 1778 | 0.530 |
Why?
|
Clinical Competence | 2 | 2018 | 206 | 0.510 |
Why?
|
Cystatin C | 1 | 2015 | 3 | 0.490 |
Why?
|
Automation | 1 | 2014 | 10 | 0.470 |
Why?
|
Image-Guided Biopsy | 1 | 2014 | 37 | 0.460 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 33 | 0.440 |
Why?
|
Plasmapheresis | 6 | 2013 | 13 | 0.380 |
Why?
|
Eosinophilia | 3 | 2011 | 39 | 0.380 |
Why?
|
Renal Insufficiency | 3 | 2006 | 12 | 0.380 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2011 | 5 | 0.370 |
Why?
|
Pruritus | 1 | 2011 | 10 | 0.370 |
Why?
|
Severity of Illness Index | 7 | 2019 | 879 | 0.370 |
Why?
|
Time Factors | 7 | 2018 | 1433 | 0.370 |
Why?
|
Silicones | 1 | 2011 | 11 | 0.370 |
Why?
|
Catheters, Indwelling | 1 | 2011 | 23 | 0.370 |
Why?
|
Follow-Up Studies | 13 | 2014 | 1792 | 0.370 |
Why?
|
Internship and Residency | 2 | 2014 | 211 | 0.350 |
Why?
|
Prednisone | 10 | 2019 | 66 | 0.350 |
Why?
|
Reproducibility of Results | 5 | 2021 | 676 | 0.340 |
Why?
|
Glomerular Filtration Rate | 5 | 2015 | 39 | 0.340 |
Why?
|
Lupus Erythematosus, Systemic | 6 | 1999 | 190 | 0.340 |
Why?
|
Retrospective Studies | 19 | 2023 | 3538 | 0.330 |
Why?
|
Aged | 25 | 2021 | 8997 | 0.320 |
Why?
|
Peritoneum | 6 | 2000 | 15 | 0.310 |
Why?
|
Remission Induction | 6 | 2013 | 90 | 0.310 |
Why?
|
Recurrence | 6 | 2019 | 310 | 0.310 |
Why?
|
Anemia | 4 | 1995 | 34 | 0.300 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2008 | 3 | 0.300 |
Why?
|
Ultrasonography, Interventional | 3 | 2018 | 69 | 0.290 |
Why?
|
Survival Rate | 9 | 2013 | 342 | 0.290 |
Why?
|
Bacterial Infections | 2 | 2000 | 51 | 0.290 |
Why?
|
Equipment Design | 2 | 2021 | 138 | 0.290 |
Why?
|
AIDS-Associated Nephropathy | 4 | 2011 | 7 | 0.290 |
Why?
|
Adolescent | 10 | 2014 | 2172 | 0.270 |
Why?
|
Multiple Myeloma | 1 | 2006 | 19 | 0.260 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2003 | 18 | 0.260 |
Why?
|
Anti-Inflammatory Agents | 4 | 2019 | 79 | 0.250 |
Why?
|
Erythropoietin | 4 | 1995 | 7 | 0.250 |
Why?
|
Cyclosporins | 2 | 1998 | 3 | 0.240 |
Why?
|
Hemorrhage | 4 | 2009 | 81 | 0.240 |
Why?
|
Kidney Transplantation | 4 | 1994 | 119 | 0.230 |
Why?
|
Hematoma | 3 | 2009 | 19 | 0.230 |
Why?
|
Young Adult | 7 | 2014 | 1994 | 0.210 |
Why?
|
Methylprednisolone | 1 | 2003 | 20 | 0.210 |
Why?
|
Renal Replacement Therapy | 2 | 2019 | 17 | 0.200 |
Why?
|
Ultrasonography | 3 | 2014 | 227 | 0.200 |
Why?
|
Aged, 80 and over | 11 | 2014 | 4777 | 0.200 |
Why?
|
Nephrosis | 3 | 2004 | 3 | 0.200 |
Why?
|
Multivariate Analysis | 5 | 2019 | 329 | 0.190 |
Why?
|
Urban Population | 2 | 2000 | 153 | 0.190 |
Why?
|
Risk Factors | 11 | 2011 | 2302 | 0.190 |
Why?
|
Hypertension | 4 | 2018 | 192 | 0.190 |
Why?
|
Ethylene Glycol | 1 | 2001 | 3 | 0.180 |
Why?
|
Antidotes | 1 | 2001 | 3 | 0.180 |
Why?
|
Mycoses | 1 | 2000 | 21 | 0.180 |
Why?
|
Polycystic Kidney Diseases | 1 | 2000 | 4 | 0.170 |
Why?
|
von Hippel-Lindau Disease | 1 | 2000 | 5 | 0.170 |
Why?
|
Pyrazoles | 1 | 2001 | 59 | 0.170 |
Why?
|
Survival Analysis | 6 | 2007 | 257 | 0.170 |
Why?
|
Child | 9 | 2009 | 1295 | 0.170 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2000 | 39 | 0.160 |
Why?
|
Carcinoma, Renal Cell | 1 | 2000 | 46 | 0.160 |
Why?
|
Dialysis Solutions | 2 | 1998 | 4 | 0.160 |
Why?
|
Kidney Neoplasms | 1 | 2000 | 78 | 0.160 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 1998 | 110 | 0.160 |
Why?
|
Immune Complex Diseases | 2 | 1992 | 2 | 0.160 |
Why?
|
Amlodipine | 1 | 2018 | 3 | 0.150 |
Why?
|
Lisinopril | 1 | 2018 | 3 | 0.150 |
Why?
|
Labetalol | 1 | 2018 | 4 | 0.150 |
Why?
|
Nicardipine | 1 | 2018 | 4 | 0.150 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 36 | 0.150 |
Why?
|
Prevalence | 4 | 2003 | 443 | 0.150 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 55 | 0.150 |
Why?
|
Vasculitis | 3 | 2005 | 26 | 0.150 |
Why?
|
Hemofiltration | 2 | 1995 | 7 | 0.140 |
Why?
|
Lung Diseases | 2 | 2005 | 45 | 0.140 |
Why?
|
Glycation End Products, Advanced | 2 | 1994 | 7 | 0.140 |
Why?
|
Treatment Outcome | 10 | 2010 | 3485 | 0.140 |
Why?
|
Urban Health | 2 | 1995 | 22 | 0.130 |
Why?
|
Logistic Models | 2 | 2014 | 395 | 0.130 |
Why?
|
Drug Resistance | 2 | 2012 | 47 | 0.130 |
Why?
|
Liver Transplantation | 2 | 1995 | 89 | 0.130 |
Why?
|
Biomarkers | 1 | 2019 | 562 | 0.130 |
Why?
|
Liver Failure | 1 | 1995 | 10 | 0.120 |
Why?
|
Glomerulonephritis, Membranoproliferative | 2 | 1996 | 2 | 0.120 |
Why?
|
Disease Progression | 4 | 2011 | 673 | 0.110 |
Why?
|
Pregnancy Complications | 2 | 2005 | 45 | 0.110 |
Why?
|
Actin Cytoskeleton | 1 | 1994 | 6 | 0.110 |
Why?
|
Ultrafiltration | 3 | 2000 | 4 | 0.110 |
Why?
|
Blood Pressure Determination | 1 | 1994 | 14 | 0.110 |
Why?
|
Thrombosis | 2 | 1993 | 54 | 0.110 |
Why?
|
Peritoneal Diseases | 2 | 1998 | 4 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2009 | 80 | 0.100 |
Why?
|
Hematocrit | 2 | 1995 | 15 | 0.100 |
Why?
|
Phosphorus | 1 | 2012 | 6 | 0.100 |
Why?
|
Ferric Compounds | 1 | 2012 | 4 | 0.100 |
Why?
|
Chelating Agents | 1 | 2012 | 13 | 0.100 |
Why?
|
Blood Pressure | 1 | 1994 | 195 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 1993 | 127 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2008 | 278 | 0.100 |
Why?
|
Apolipoproteins | 1 | 2011 | 6 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2011 | 23 | 0.090 |
Why?
|
Patch Tests | 1 | 2011 | 2 | 0.090 |
Why?
|
Renal Artery Obstruction | 1 | 1991 | 3 | 0.090 |
Why?
|
Exanthema | 1 | 2011 | 12 | 0.090 |
Why?
|
Anti-Glomerular Basement Membrane Disease | 1 | 1989 | 1 | 0.080 |
Why?
|
Endocarditis, Bacterial | 1 | 1989 | 11 | 0.080 |
Why?
|
Case-Control Studies | 4 | 2011 | 587 | 0.080 |
Why?
|
Amyloidosis | 2 | 2006 | 20 | 0.080 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 2 | 2009 | 7 | 0.080 |
Why?
|
Diet | 1 | 2010 | 220 | 0.080 |
Why?
|
Molecular Motor Proteins | 1 | 2008 | 1 | 0.080 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2008 | 10 | 0.080 |
Why?
|
Mutation | 2 | 2007 | 348 | 0.080 |
Why?
|
Hypertension, Renal | 2 | 2002 | 3 | 0.080 |
Why?
|
Myosin Heavy Chains | 1 | 2008 | 8 | 0.080 |
Why?
|
Treatment Failure | 2 | 2002 | 158 | 0.080 |
Why?
|
Hemolysis | 1 | 2008 | 5 | 0.080 |
Why?
|
Haplotypes | 1 | 2008 | 58 | 0.080 |
Why?
|
Poisson Distribution | 2 | 2000 | 22 | 0.080 |
Why?
|
Heart Valve Prosthesis | 1 | 2008 | 12 | 0.070 |
Why?
|
Mitral Valve | 1 | 2008 | 9 | 0.070 |
Why?
|
Aortic Valve | 1 | 2008 | 24 | 0.070 |
Why?
|
Age Factors | 3 | 2019 | 766 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2008 | 42 | 0.070 |
Why?
|
Lipoproteins | 1 | 2007 | 10 | 0.070 |
Why?
|
Apolipoprotein E2 | 1 | 2007 | 12 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2007 | 24 | 0.070 |
Why?
|
Glomerulonephritis, Membranous | 3 | 2001 | 3 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 49 | 0.070 |
Why?
|
Genotype | 4 | 2011 | 346 | 0.070 |
Why?
|
Patient Compliance | 2 | 2000 | 150 | 0.070 |
Why?
|
Nursing Homes | 1 | 2007 | 36 | 0.070 |
Why?
|
Skilled Nursing Facilities | 1 | 2007 | 31 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2007 | 165 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 381 | 0.070 |
Why?
|
Staphylococcus epidermidis | 2 | 1996 | 4 | 0.060 |
Why?
|
Anemia, Pernicious | 1 | 1986 | 1 | 0.060 |
Why?
|
Autoantibodies | 1 | 2006 | 80 | 0.060 |
Why?
|
Biological Transport | 2 | 1998 | 39 | 0.060 |
Why?
|
Immunity, Maternally-Acquired | 1 | 2005 | 1 | 0.060 |
Why?
|
Pedigree | 2 | 2007 | 65 | 0.060 |
Why?
|
Isoantibodies | 1 | 2005 | 7 | 0.060 |
Why?
|
Genes, Wilms Tumor | 1 | 2005 | 1 | 0.060 |
Why?
|
Population | 1 | 2005 | 5 | 0.060 |
Why?
|
Diabetes Insipidus | 1 | 1985 | 1 | 0.060 |
Why?
|
Analysis of Variance | 2 | 1996 | 260 | 0.060 |
Why?
|
Ambulatory Care | 2 | 1996 | 69 | 0.060 |
Why?
|
Laryngeal Diseases | 1 | 1984 | 3 | 0.060 |
Why?
|
Chicago | 2 | 1999 | 949 | 0.060 |
Why?
|
Blood Transfusion | 3 | 1996 | 67 | 0.060 |
Why?
|
Coronary Disease | 1 | 1984 | 50 | 0.060 |
Why?
|
Algorithms | 1 | 2006 | 350 | 0.060 |
Why?
|
Staphylococcal Infections | 2 | 1996 | 162 | 0.060 |
Why?
|
Cyclophosphamide | 3 | 2010 | 48 | 0.050 |
Why?
|
Nephrons | 1 | 2003 | 6 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 474 | 0.050 |
Why?
|
Diabetic Nephropathies | 2 | 1994 | 17 | 0.050 |
Why?
|
Educational Status | 2 | 1995 | 293 | 0.050 |
Why?
|
Contraindications | 1 | 2002 | 31 | 0.050 |
Why?
|
Radiography, Interventional | 1 | 2002 | 17 | 0.050 |
Why?
|
Immunoglobulins | 2 | 1992 | 14 | 0.050 |
Why?
|
Suicide, Attempted | 1 | 2001 | 14 | 0.050 |
Why?
|
New York City | 1 | 2000 | 12 | 0.040 |
Why?
|
Complement C3 | 3 | 1990 | 4 | 0.040 |
Why?
|
Incidence | 3 | 2000 | 759 | 0.040 |
Why?
|
Urea | 2 | 1996 | 10 | 0.040 |
Why?
|
Education, Medical, Graduate | 1 | 2000 | 77 | 0.040 |
Why?
|
Age of Onset | 2 | 2011 | 94 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 216 | 0.040 |
Why?
|
Curriculum | 1 | 2000 | 138 | 0.040 |
Why?
|
Forecasting | 2 | 1996 | 91 | 0.040 |
Why?
|
Body Mass Index | 1 | 2002 | 458 | 0.040 |
Why?
|
Sclerosis | 1 | 1999 | 66 | 0.040 |
Why?
|
Capillary Action | 1 | 1998 | 1 | 0.040 |
Why?
|
Lymph | 1 | 1998 | 1 | 0.040 |
Why?
|
Fluid Shifts | 1 | 1998 | 1 | 0.040 |
Why?
|
Glycosylation | 1 | 1998 | 19 | 0.040 |
Why?
|
Treatment Refusal | 1 | 1998 | 11 | 0.040 |
Why?
|
Tissue Adhesions | 1 | 1998 | 10 | 0.040 |
Why?
|
Microtubules | 2 | 1991 | 28 | 0.040 |
Why?
|
Water | 1 | 1998 | 30 | 0.040 |
Why?
|
Catheterization | 1 | 1998 | 41 | 0.040 |
Why?
|
Genetic Variation | 2 | 2011 | 96 | 0.040 |
Why?
|
Edema | 2 | 1996 | 25 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 347 | 0.040 |
Why?
|
Microscopy, Electron | 3 | 2002 | 65 | 0.040 |
Why?
|
Syndrome | 2 | 2005 | 76 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2019 | 1368 | 0.040 |
Why?
|
Databases, Factual | 1 | 2019 | 347 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 348 | 0.030 |
Why?
|
Iron | 2 | 2012 | 14 | 0.030 |
Why?
|
United States | 4 | 2011 | 2035 | 0.030 |
Why?
|
Child, Preschool | 1 | 1998 | 641 | 0.030 |
Why?
|
Ciprofloxacin | 1 | 1995 | 11 | 0.030 |
Why?
|
Weight Gain | 1 | 1996 | 64 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 1996 | 302 | 0.030 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 1995 | 23 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 1995 | 139 | 0.030 |
Why?
|
Sepsis | 1 | 1996 | 113 | 0.030 |
Why?
|
Sex Factors | 1 | 1996 | 464 | 0.030 |
Why?
|
Uremia | 1 | 1994 | 4 | 0.030 |
Why?
|
Double-Blind Method | 2 | 1995 | 406 | 0.030 |
Why?
|
Risk Assessment | 1 | 1996 | 624 | 0.030 |
Why?
|
Pregnancy | 2 | 2005 | 336 | 0.030 |
Why?
|
Hypertrophy | 1 | 1993 | 24 | 0.030 |
Why?
|
Canada | 3 | 2000 | 47 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 1994 | 68 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 90 | 0.030 |
Why?
|
Regression Analysis | 1 | 1994 | 260 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 1995 | 181 | 0.030 |
Why?
|
Postoperative Complications | 2 | 1991 | 916 | 0.030 |
Why?
|
Ferritins | 1 | 2012 | 4 | 0.030 |
Why?
|
Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2012 | 3 | 0.030 |
Why?
|
Color | 1 | 2012 | 7 | 0.030 |
Why?
|
Constipation | 1 | 2012 | 16 | 0.030 |
Why?
|
Complement System Proteins | 1 | 1992 | 8 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1992 | 32 | 0.020 |
Why?
|
Seizures | 1 | 1993 | 67 | 0.020 |
Why?
|
Substance Abuse, Intravenous | 1 | 1992 | 10 | 0.020 |
Why?
|
Feces | 1 | 2012 | 103 | 0.020 |
Why?
|
Quality of Life | 2 | 1996 | 629 | 0.020 |
Why?
|
Human Genome Project | 1 | 2011 | 1 | 0.020 |
Why?
|
HapMap Project | 1 | 2011 | 1 | 0.020 |
Why?
|
Apolipoprotein L1 | 1 | 2011 | 4 | 0.020 |
Why?
|
Nephritis, Interstitial | 2 | 1995 | 3 | 0.020 |
Why?
|
Renal Artery | 1 | 1991 | 8 | 0.020 |
Why?
|
Crystallization | 1 | 1991 | 4 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 175 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 1994 | 235 | 0.020 |
Why?
|
Neoplasms | 1 | 1993 | 237 | 0.020 |
Why?
|
Graft Rejection | 1 | 1990 | 68 | 0.020 |
Why?
|
Cryoglobulinemia | 1 | 1989 | 1 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 1989 | 28 | 0.020 |
Why?
|
Acute Disease | 1 | 1989 | 176 | 0.020 |
Why?
|
Hemodynamics | 1 | 1989 | 63 | 0.020 |
Why?
|
Lod Score | 1 | 2008 | 20 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2008 | 42 | 0.020 |
Why?
|
DNA Primers | 1 | 2008 | 52 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2008 | 58 | 0.020 |
Why?
|
Lung | 1 | 1989 | 168 | 0.020 |
Why?
|
Cohort Studies | 2 | 2009 | 1890 | 0.020 |
Why?
|
Genome, Human | 1 | 2008 | 50 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 1988 | 8 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 1991 | 321 | 0.020 |
Why?
|
Administration, Oral | 1 | 2007 | 108 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 482 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 161 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2012 | 1144 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2007 | 68 | 0.020 |
Why?
|
Arteriosclerosis | 1 | 1987 | 11 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2007 | 56 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 1996 | 43 | 0.020 |
Why?
|
Prescriptions | 2 | 1996 | 16 | 0.020 |
Why?
|
Clinical Protocols | 2 | 1996 | 57 | 0.020 |
Why?
|
Animals | 1 | 1994 | 3642 | 0.020 |
Why?
|
Intrinsic Factor | 1 | 1986 | 1 | 0.020 |
Why?
|
Schilling Test | 1 | 1986 | 1 | 0.020 |
Why?
|
Antibodies | 1 | 1986 | 46 | 0.020 |
Why?
|
Hemoglobins | 1 | 1986 | 33 | 0.020 |
Why?
|
Cryoglobulins | 1 | 1985 | 1 | 0.020 |
Why?
|
Glomerular Mesangium | 1 | 1985 | 2 | 0.020 |
Why?
|
Basement Membrane | 1 | 1985 | 11 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 2005 | 6 | 0.020 |
Why?
|
Peroxidase | 1 | 2005 | 14 | 0.020 |
Why?
|
Fetal Blood | 1 | 2005 | 13 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 1985 | 79 | 0.020 |
Why?
|
Denys-Drash Syndrome | 1 | 2005 | 1 | 0.010 |
Why?
|
Frasier Syndrome | 1 | 2005 | 1 | 0.010 |
Why?
|
Autoantigens | 1 | 2005 | 26 | 0.010 |
Why?
|
Kidney Concentrating Ability | 1 | 1985 | 1 | 0.010 |
Why?
|
Pre-Eclampsia | 1 | 1985 | 6 | 0.010 |
Why?
|
Cesarean Section | 1 | 2005 | 30 | 0.010 |
Why?
|
Exons | 1 | 2005 | 33 | 0.010 |
Why?
|
Vasopressins | 1 | 1985 | 8 | 0.010 |
Why?
|
Antigen-Antibody Complex | 1 | 2004 | 4 | 0.010 |
Why?
|
Emergencies | 1 | 2005 | 32 | 0.010 |
Why?
|
Eosinophils | 1 | 1985 | 44 | 0.010 |
Why?
|
Capillaries | 1 | 2004 | 11 | 0.010 |
Why?
|
Dyspnea | 1 | 2005 | 41 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 1996 | 261 | 0.010 |
Why?
|
Cyclosporine | 1 | 2004 | 12 | 0.010 |
Why?
|
Airway Obstruction | 1 | 1984 | 20 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2005 | 85 | 0.010 |
Why?
|
Phenotype | 1 | 2005 | 312 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1984 | 133 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2005 | 642 | 0.010 |
Why?
|
World Health Organization | 1 | 2001 | 9 | 0.010 |
Why?
|
International Cooperation | 1 | 2000 | 15 | 0.010 |
Why?
|
Osmotic Pressure | 1 | 2000 | 5 | 0.010 |
Why?
|
Water-Electrolyte Balance | 1 | 2000 | 4 | 0.010 |
Why?
|
Demography | 1 | 2000 | 72 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2000 | 57 | 0.010 |
Why?
|
Minority Groups | 1 | 2000 | 80 | 0.010 |
Why?
|
Body Surface Area | 1 | 1996 | 3 | 0.010 |
Why?
|
Nutritional Physiological Phenomena | 1 | 1996 | 5 | 0.010 |
Why?
|
Consensus Development Conferences as Topic | 1 | 1996 | 6 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 1996 | 32 | 0.010 |
Why?
|
Permeability | 1 | 1996 | 97 | 0.010 |
Why?
|
Nutritional Status | 1 | 1996 | 58 | 0.010 |
Why?
|
Leukocyte Count | 2 | 1987 | 61 | 0.010 |
Why?
|
Social Environment | 1 | 1996 | 76 | 0.010 |
Why?
|
Necrosis | 1 | 1995 | 26 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 1995 | 22 | 0.010 |
Why?
|
Life Style | 1 | 1996 | 186 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 1995 | 12 | 0.010 |
Why?
|
Epithelium | 1 | 1989 | 31 | 0.000 |
Why?
|
Complement C4 | 1 | 1987 | 3 | 0.000 |
Why?
|
Antibodies, Antinuclear | 1 | 1987 | 12 | 0.000 |
Why?
|
Pyuria | 1 | 1985 | 1 | 0.000 |
Why?
|
Urinary Tract Infections | 1 | 1985 | 31 | 0.000 |
Why?
|